

# Renovascular Hypertension for the USMLE Step One Exam



4

	LVEDP	LVEDV	LVEF
A.	Inc	Inc	Dec
B.	NI	Inc	Dec
C.	NI	NI	Dec
D.	Inc	NI	Dec
E.	Inc	NI	NI
F.	NI	Inc	NI

Pharmacology Mischief

Indication

Agent MOA

Adverse Effects

TRADE MARK

ARS GRATIA MARI

etio G Mayo



100% 80% 80%

GFR

Filtration Fraction = GFR/RPF = ~20%

A complex medical diagram featuring a central image of a lion's head within a circular frame labeled 'ARS GRATIA MARI'. The lion is surrounded by a film strip. To the left is a diagram of a nephron showing RPF (Renal Plasma Flow) and GFR (Glomerular Filtration Rate) with percentages (100%, 80%, 80%) and a calculation for Filtration Fraction = GFR/RPF = ~20%. To the right is a photograph of a kidney. The number '4' is prominently displayed in a purple circle at the top.

Howard J. Sachs, MD  
Associate Professor of Medicine  
University of Massachusetts Medical School  
[www.12DaysinMarch.com](http://www.12DaysinMarch.com); Season III  
E-mail: [Howard@12daysinmarch.com](mailto:Howard@12daysinmarch.com)





*Stenosis Physiology and Related Pathology*

The Key Players in *Renovascular* HTN

*Vascular Pathology*

*Hyperplastic arteriolitis*



*Arteriolar Hyalinosis*



*Nephrosclerosis*

# Renovascular Disorders (key derivative topics)

- Malignant HTN (physiology, pathology, pharmacology)
- *Arteriolosclerosis → Nephrosclerosis (pathology)*
- Renal Artery Stenosis (physiology and consequences)
  - *Fibromuscular Dysplasia (diagnostics, pathology)*
  - *Takayasu's Arteritis (pathology)*



Arteriolosclerosis → Nephrosclerosis




Kidney


Scarring



# Arteriolosclerosis → Nephrosclerosis




# Arteriolosclerosis → Nephrosclerosis




# Arteriolosclerosis → Nephrosclerosis

*Outside*

*Inside (renal parenchyma)*



*Granular  
Cortical scarring*




*Tubular atrophy, Interstitial fibrosis  
Glomerulosclerosis*

# Arteriolosclerosis → Nephrosclerosis

- Background

- **Nephrosclerosis** is a pathologic diagnosis characterized by:
  - Reduction in renal function secondary to parenchymal ischemia
- **Primary Lesion:** **Hyalinosis** typically as a result of HTN and DM
- **Presentation:** HTN/DM with reduced GFR (+/- *mild* proteinuria).
  - *In the clinic:* ‘Longstanding diabetic/HTN with CKD **presumably** 2° to nephrosclerosis’







# Arteriolosclerosis → Nephrosclerosis

- Background


- **Nephrosclerosis** is a pathologic diagnosis characterized by:
  - Reduction in renal function secondary to parenchymal ischemia
- **Primary Lesion:** **Hyalinosis** typically as a result of HTN and DM
- **Presentation:** HTN/DM with reduced GFR (+/- *mild* proteinuria).
  - *In the clinic:* 'Longstanding diabetic/HTN with CKD **presumably** 2° to nephrosclerosis'




*Malignant → HTN  
Hyperplastic arteriolitis*



*Hyalinosis*



*(Diabetic) Nodular  
Glomerulosclerosis*




Thickening → Narrowing of lumen  
(*obliterative arteriopathy*)  
Result: *Parenchymla Ischemia*

\*AGE: *advanced glycated end products*

- Pathogenesis

- Small arteries: medial and intimal **thickening** related to hemodynamic injury. Lumen becomes narrow → focal parenchymal ischemia with **reduction in functional renal mass**.




Thickening → Narrowing of lumen  
(*obliterative arteriopathy*)  
Result: *Parenchymla Ischemia*

\*AGE: *advanced glycated end products*


## • Pathogenesis

- Small arteries: medial and intimal thickening related to hemodynamic injury. Lumen becomes narrow → focal parenchymal ischemia with reduction in functional renal mass.
- Hyalinization (*due endothelial injury*): **extravasation of proteins** (AGE) and increased deposition of **BM matrix** (*elaborated by smooth mm cells*)



Thickening → Narrowing of lumen  
(*obliterative arteriopathy*)  
Result: *Parenchymla Ischemia*

\*AGE: *advanced glycated end products*



- Pathology

- Artery: **homogenous, acellular** thickening of vessel wall
- Kidney: Tubular atrophy, interstitial fibrosis, glomerular sclerosis




*Macroscopic*




**Nephrosclerosis**  
Reduced size, cortical scarring  
and a ***granular appearance***

*Microscopic  
(nonspecific reflecting chronic vascular injury)*



# Arteriolosclerosis → Nephrosclerosis


Physiology derivative: Filtration Fraction





$$\text{Filtration Fraction} = \text{GFR}/\text{RPF} = \sim 20\%$$

# Arteriolosclerosis → Nephrosclerosis

Physiology derivative: Filtration Fraction



HTN  
DM




DM

$$\text{Filtration Fraction} = \text{GFR/RPF} = \sim 20\%$$


# Arteriolosclerosis → Nephrosclerosis

Physiology derivative: Filtration Fraction





$$\text{Filtration Fraction} = \text{GFR}/\text{RPF} = \sim 20\%$$






How does efferent arteriole 'constriction' affect filtration fraction?






What happens to filtration fraction if you relieve the 'stricture' with an ACE-I?



**Filtration Fraction** (*efferent stricture*):  $GFR \downarrow / \uparrow RPF = \downarrow FF$







# Hypertensive (DM) Nephrosclerosis



- Background

- Ischemic parenchymal injury 2° to *hemodynamic injury* (typically in setting of *HTN/DM*)

- Pathogenesis

- Elaboration of *extracellular matrix* and/or *advanced glycation end products* (DM) by vascular smooth mm cells

- Pathology

- Micro: Efferent arteriole hyalinosis (acellular, homogenous thickening) resulting in *tubulointerstitial fibrosis* and *glomerulosclerosis*
- Macro: *Cortical scarring* with granular appearance and reduction in renal mass.

- Physiology Derivative

- Impact on GFR and renal plasma flow (= *filtration fraction* with and without ACE-I)

# Primary (Essential) Hypertension for the Boards

Older patient with diastolic heart disease

'...an extra pre-systolic heart sound is heard at the apex


'Patient with HTN is started on which of the following agents...'

	LVEDP	LVEDV	LVEF
A.	Inc	Inc	Dec
B.	NI	Inc	Dec
C.	NI	NI	Dec
D.	Inc	NI	Dec
E.	Inc	NI	NI
F.	NI	Inc	NI



Atrium contracting against a poorly compliant ventricle (at limit of compliance)


## Pharmacology Mischief






# Primary (Essential) Hypertension for the Boards

	LVEDP	LVEDV	LVEF
A.	Inc	Inc	Dec
B.	NI	Inc	Dec
C.	NI	NI	Dec
D.	Inc	NI	Dec
E.	Inc	NI	NI
F.	NI	Inc	NI

4



The End



# Renovascular Hypertension for the USMLE Step One Exam



4

	LVEDP	LVEDV	LVEF
A.	Inc	Inc	Dec
B.	NI	Inc	Dec
C.	NI	NI	Dec
D.	Inc	NI	Dec
E.	Inc	NI	NI
F.	NI	Inc	NI

Pharmacology Mischief

Indication  
Agent  
MOA  
Adverse Effects

The End

100% → RPF → 80% 80%

GFR

Filtration Fraction = GFR/RPF = ~30%



Howard J. Sachs, MD  
Associate Professor of Medicine  
University of Massachusetts Medical School  
[www.12DaysinMarch.com](http://www.12DaysinMarch.com); Season III  
E-mail: [Howard@12daysinmarch.com](mailto:Howard@12daysinmarch.com)